信義香港(08328.HK)擬1.44億元出售嘉德威(杭州)生物科技100%股權
格隆匯5月17日丨信義香港(08328.HK)宣佈,於2020年5月15日,杭州雲棲(作為買方)與恆有源投資(公司的全資附屬公司,作為賣方)訂立股權轉讓協議,據此,恆有源投資有條件地同意出售而杭州雲棲有條件地同意購買嘉德威(杭州)生物科技100%股權,代價為人民幣1.44億元。所得款項將用作集團一般營運資金包括償還貸款。
據悉,嘉德威(杭州)生物科技所持土地物業位於中國浙江省杭州市西湖區轉塘街道轉塘科技經濟區6號,土地面積約29,976平方米,其上巳建有3座綜合工業及辦公室大樓,合共建築面積約24,320平方米。授出土地使用權為工業用地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.